TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00516724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Intravenous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KU-0059436 (AZD2281)(PARP inhibitor)
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel + Carboplatin
Description: Intravenous injection
Study: NCT02180789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin OCAS
Description: oral
Study: NCT01282073

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil, low dose steroid
Description: Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 \~ 1000 mg bid per day (more than 50kg)~Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day~Duration: 48 weeks
Study: NCT03829865

Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution esophageal manometry
Description: High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study

Intervention type: DIAGNOSTIC_TEST
Intervention: High resolution esophageal manometry
Description: High resolution esophageal manometry will be performed to eligible subjects willing to participate in the study
Study: NCT01282073

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporin, low dose steroid
Description: Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)~Steroid: same dosage with active comparator goup~Duration: 48 weeks
Study: NCT05314660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38 % silver diamine fluoride
Description: Application of 38% SDF on carious dentine lesions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative technique
Description: Hand excavation of carious dentine followed by application of Glass ionomer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultra conservative dentistry
Description: Removal of soft dentine and enlarging of cavity to control bio film
Study: NCT01145950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LBEC0101
Description: Etanercept 25mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enbrel
Description: Etanercept 25mg, single dose
Study: NCT01116284

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revision of gastric bypass
Description: A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
Study: NCT01597739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-40346527
Description: Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=capsule; route=oral use; twice daily.
Study: NCT03235050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 low dose
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 mid dose
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI0382 high dose
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: solution Route of administration: subcutaneous

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Pharmaceutical form: solution Route of administration: subcutaneous
Study: NCT02232087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study: NCT00784524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic large multivalent immunogen breast cancer vaccine
Description: Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10\^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
Study: NCT02232087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study: NCT02823002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow, Room Temperature Injection
Description: The room temperature local anesthetic agent will be administered by slow infiltration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid, Room Temperature Injection
Description: The room temperature local anesthetic agent will be administered by rapid infiltration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Slow, Warm Temperature Injection
Description: The warmed local anesthetic agent will be administered by slow infiltration.
Study: NCT02232087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study: NCT02711839

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Commercial diabetic formula
Description: The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: White sweet potato formula
Description: The formula were supplied 1500\~1800 kcal daily depend on the patient's individual situation
Study: NCT02823002

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rapid, Warm Temperature Injection
Description: The warmed local anesthetic agent will be administered by rapid infiltration.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Buffered Injection
Description: One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Non-Buffered Injection
Description: One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
Study: NCT03294759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bio ACL
Description: Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Normal ACL reconstruction technique with either patella or hamstring autograft
Study: NCT02232087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study: NCT01133522

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study: NCT02989545

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Anal Tape
Study: NCT02232087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone propionate
Description: A, D 2 puffs; B, E 6 puffs; C, F 12 puffs
Study: NCT03266666

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: WellnessRX Lifestyle Change Classes
Description: Lifestyle change classes on nutrition, physical activity, and stress management.

Intervention type: OTHER
Group type: OTHER
Intervention: Thrive Market Grocery Credits (4x$25 each)
Description: Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
Study: NCT00304317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: celecoxib
Description: Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
Study: NCT00784524

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Subcutaneous aldesleukin (10 x 10\^6 International Units) will be given on day 7 and day 8 after each LMI injection.
Study: NCT00844636

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sharp needle

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Blunt needles
Study: NCT02875938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simultaneous music and reading lyrics
Description: music with sung lyrics simultaneously with silent reading of the lyrics.
Study: NCT04347226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 2400mg IV at 0 and 2 weeks (if patient is still hospitalized) and then 4 weeks (only if still hospitalized with continued severe respiratory disease).
Study: NCT02851433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: total anaesthesia and postoperative inhaled sedation with Sevoflurane

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: total intravenous anaesthesia with Propofol.
Study: NCT01182389

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Robotic VT Ablation
Description: Robotic VT Ablation
Study: NCT05628558

Intervention type: DRUG
Intervention: Desmopressin
Description: The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care.

Intervention type: DRUG
Intervention: Desmopressin
Description: The interventions with desmopressin recorded in this study were all realized following the internationally recommended standard care of patients with mild/moderate hemophilia A. They were all retrospectively collected. These interventions comprised:~* An intravenous administration of desmopressin infused during 30 minutes at a dosage of 0,3-0,4 µg/Kg~* Measurements of Factor and von Willebrand factors levels just before the desmopressin infusion and after at 30 minutes, 1 hour, 2 hours, 4 hours and for some patients 6 hours and 24 hours.~The F8 gene variants were also diagnosed in the standard care.
Study: NCT03349827

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: exploratory laparoscopy or laparotomy
Description: Exploratory laparoscopy or laparotomy, for PCI score or radical gastrectomy and cytoreductive surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIPEC
Description: Normal saline 3000ml-4000ml, Docetaxel 50mg/m2, Lobaplatin 50mg/m2, 43°C, 60min.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Systemic chemotherapy
Description: Oxaliplatin: 130mg/m2, day 1. S1: 60mg, twice daily, day 1 to day 14. S1:60mg twice daily for two weeks, and then suspend for one week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: 500mg, once daily, day 1 to day 21.
Study: NCT02823002

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
Study: NCT02875938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Priming with music
Description: priming with music and sung lyrics followed by reading of the lyrics.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: control condition using reading materials without music.
Study: NCT02565069

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CartoFinder™ Device with CARTO® 3 System V5 Navigation
Description: Ablation treatment
Study: NCT02823002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffer
Description: Sodium Bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffer
Description: Sodium Bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffer
Description: Sodium Bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffer
Description: Sodium Bicarbonate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buffer
Description: Sodium Bicarbonate
Study: NCT00276419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diclofenac
Description: Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
Study: NCT02667743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Micelles for Injection
Study: NCT00276419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
Study: NCT01968343

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy.
Description: Subjects receive 22 sessions of cognitive-behavioral therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supportive therapy.
Description: Subjects receive 22 sessions of supportive therapy.
Study: NCT03461718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Experimental arm for sedation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam injection
Description: Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam injection
Description: Part of standard sedation regimen and anxiolysis and for minimization of emergence reaction
Study: NCT02667743

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel Injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Study: NCT02810080

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed Loop Control Ventilation
Description: Closed loop control ventilation using ZOLL 731 ventilator with physiologic closed-loop control software

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Control Ventilation
Description: Manual control ventilation using ZOLL 731 ventilator
Study: NCT01128790

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning
Description: 4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
Study: NCT03461718

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Part of standard sedation regimen
Study: NCT01128790

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Control
Description: 4 cycles x 5mins blood pressure cuff inflation to 10mmHg
Study: NCT02304913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglossal acupuncture
Study: NCT00688597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvoglustat
Description: Powder in a bottle for dissolution in water for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvoglustat
Description: Powder in a bottle for dissolution in water for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duvoglustat
Description: Powder in a bottle for dissolution in water for oral administration
Study: NCT01923636

Intervention type: OTHER
Group type: OTHER
Intervention: detection of CMV
Description: Clinical, radiological and laboratory (virological and immunological) standardized reports
Study: NCT03681756

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WALK
Description: Walking program
Study: NCT03817684

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: Drug BPN14770

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BPN14770
Description: Drug BPN14770

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01263119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin
Description: 10-mg warfarin oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2216684
Description: 18-mg LY2216684 oral dose
Study: NCT03997032

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ocufolin
Description: Ocufolin, Aprofol AG, Switzerland Dose: 1 capsule per day
Study: NCT02138825

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
Study: NCT02683902

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active tDCS
Description: The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Hypocaloric diet
Description: A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Hypocaloric diet
Description: A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
Study: NCT01182389

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Therapy
Description: Review of ICD programming to ensure that detection and therapy will occur appropriately